Skip to main content

Mayer Brown JSM and Hogan Lovells have advised the government of Mongolia on a $500 million sovereign bond offering under its $5 billion Global Medium Term Note Programme, its first offering since 2012. 

Allen & Overy and local firm GTs Advocates acted for the joint lead managers, which includes Credit Suisse, Deutsche Bank, ING and JPMorgan Chase as well as local banks TDB Capital and Golomt Bank and TDB Capital. 

Corporate and securities group partners Jason T. Elder and Tom Kollar handled the transaction for Mayer Brown. The Hogan Lovells team was led by Chris Melville in Ulaanbaatar and fellow partners Sina Hekmat in New York and Andrew Carey in London. Hong Kong-based partner Alexander Stathopoulos oversaw the offering for A&O

The issuance, which closed last week, was done under the government’s Global Medium Term Notes Program. The bonds were sold internationally on a combined Rule 144A / Regulation S basis, with U.S.-qualified institutional buyers accounting for a substantial portion of the total demand.

Proceeds from the offering will be used to refinance indebtedness, fund budget deficits and finances different projects including infrastructure and roads.

Related Articles

Paul Hastings, Latham lead on $827 mln LG CNS Korea IPO

Paul Hastings has advised South Korean tech services firm and LG Group member company LG CNS on its 1.2-trillion-won ($827 million) global offering and listing on the Korea Exchange, with Latham & Watkins advising the bookrunners.

SAM, Khaitan act on WeWork India’s upcoming $460 mln IPO

by Nimitt Dixit |

Shardul Amarchand Mangaldas is advising WeWork India, the Indian franchisee of U.S. shared office space manager WeWork, on its upcoming initial public offering (IPO) valued at $460 million.

MoFo, Ropes, Mori Hamada guide Bain's $3.3 bln Mitsubishi Pharma buyout

by Nimitt Dixit |

Morrison Foerster, Mori, Hamada & Matsumoto, and Ropes & Gray have advised U.S. investment fund Bain Capital on its planned 510-billion-yen ($3.3 billion) acquisition of Mitsubishi Tanabe Pharma Corporation from Mitsubishi Chemical Group Corporation.